 LOS ANGELES, Oct. 11, 2021 GLOBE NEWSWIRE -- via InvestorWire -- CNS Pharmaceuticals Inc. NASDAQ: CNSP, a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announces that it has been featured in a broadcast via NetworkNewsAudio NNA, a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers CNS Pharmaceuticals recent announcement of dosing of the first patients in its Berubicin clinical development program for the treatment of recurrent glioblastoma multiforme GBM, one of the most aggressive types of brain cancer. 